Clinical Trials Logo

Churg-Strauss Syndrome clinical trials

View clinical trials related to Churg-Strauss Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02728271 Terminated - Clinical trials for Churg-Strauss Syndrome

Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome

Start date: April 2016
Phase: Early Phase 1
Study type: Interventional

Churg-Strauss syndrome is a rare autoimmune inflammatory disease affecting medium- and small-sized blood vessels, causing asthma, abnormalities of the blood, lung diseases, and neuropathy. The main cause of death in these patients is heart attack. Without therapy, the 5-year survival in patients with Churg-Strauss syndrome is 25%. Although with the 5-year survival is increased to 62% with the appropriate therapy, many patients remain refractory to therapy. The long term outcome of these patients remains grim. The aim of this research study is to determine if suppressing the immune system using a combination of high dose chemotherapy, antibodies, and radiation followed by stem cell transplant will abolish the 'bad' immune system and let the patient's body establish a new immune system that does not attack the blood vessels.

NCT ID: NCT00424749 Terminated - Clinical trials for Churg-Strauss Syndrome

Rituxan in Churg Strauss Syndrome With Renal Involvement

Start date: June 2007
Phase: Phase 2
Study type: Interventional

Churg-Strauss Syndrome (CSS) is a disease characterized by asthma, abnormally high amounts of eosinophils (a type of white blood cell), and blood vessel inflammation. About 25% of CSS patients develop kidney disease. The goal of this pilot study was to evaluate the safety and effectiveness of Rituximab in inducing remission of kidney disease in patients with CSS.